The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Nichi-Iko to Raise 21.2 Billion Yen for Elmed Eisai Buyout
Nichi-Iko Pharmaceutical plans to issue new shares to raise 21.2 billion yen to fund the 17.1 billion yen acquisition of Eisai’s generic subsidiary Elmed Eisai announced late last month, the generic major said on April 4. The new shares will…
To read the full story
Related Article
- Nichi-Iko Takes Full Control of Eisai Generic Arm, Now Renamed “Elmed”
April 2, 2019
- Eisai’s Nichi-Iko Deal Marks Watershed in Generic Biz of Research-Driven Makers
April 3, 2018
- Alliance with Nichi-Iko “Not Due to Pessimism about Generic Drug Business,” Will Expand Lineup: Eisai CEO
March 30, 2018
- Eisai to Quit Generic Supply Biz, Transfer Subsidiary to Nichi-Iko
March 29, 2018
BUSINESS
- Bayer/Santen to Launch Eylea Bio-AG on February 2
January 9, 2026
- Nxera Bags Japan, Select APAC Rights to Santhera’s DMD Therapy
January 9, 2026
- Keio Offshoot Taps Alfresa Know-How for Cell Therapy Push, Bets on Dual iPS Strategy
January 9, 2026
- Asahi Kasei Sees Tarpeyo Uptake Outpacing Forecast, Peak Sales Can Be Higher
January 9, 2026
- Rakuten Ramps Up Photoimmunotherapy PIII with Financing, Eyes US Filing in 2028
January 9, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…